Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Vet Comp Oncol ; 15(1): 55-64, 2017 Mar.
Article in English | MEDLINE | ID: mdl-25664927

ABSTRACT

Doxorubicin has been shown to be cardiotoxic at high doses but is an efficacious chemotherapeutic agent in the treatment of canine lymphoma. Echocardiographic measurements and serum ultrasensitive cardiac troponin I (cTnI) levels were obtained before and after doxorubicin administration in 14 dogs diagnosed with lymphoma. The aim of this prospective study was to evaluate changes in cTnI concentrations and tissue velocity imaging (TVI) values in dogs with lymphoma undergoing chemotherapy with doxorubicin. A total of 182 cTnI and 1017 TVI measurements were performed. Standard echocardiographic parameters, tissue Doppler indices and cTnI concentrations did not differ at any time point within a 12-week cyclic combination protocol. In conclusion, the use of doxorubicin at standard doses in the treatment of canine lymphoma may not be associated with significant myocardial damage.


Subject(s)
Antibiotics, Antineoplastic/adverse effects , Dog Diseases/drug therapy , Doxorubicin/adverse effects , Heart/drug effects , Lymphoma/veterinary , Troponin I/blood , Analysis of Variance , Animals , Dogs , Echocardiography/methods , Echocardiography/veterinary , Female , Lymphoma/drug therapy , Male , Myocardium , Prospective Studies
2.
Vet Comp Oncol ; 14 Suppl 1: 82-94, 2016 Aug.
Article in English | MEDLINE | ID: mdl-25470748

ABSTRACT

Stage migration is described in humans and dogs as a sequel of using more sensitive diagnostic methods. One hundred eighty-six dogs with multicentric lymphoma were enrolled with results of conventional staging as well as ultrasonographic and cytological examination of liver and spleen being available. The addition of splenic respective hepatic ultrasound and cytology findings resulted in slightly lower number of dogs classified as having liver and spleen involvement. In dogs with multicentric lymphoma, addition of cytology led to a significant shift of individuals from stage IV to stage III. Findings of hepatic and splenic ultrasound and cytology exerted no significant influence on complete remission and survival durations in dogs with combination chemotherapy. Staging methodology in canine lymphoma should be redefined, considering that the prognostic significance of splenic and hepatic ultrasound and cytology warrants further investigation.


Subject(s)
Dog Diseases/pathology , Liver/pathology , Lymphoma, Non-Hodgkin/veterinary , Spleen/pathology , Animals , Dog Diseases/diagnostic imaging , Dogs , Female , Immunophenotyping/veterinary , Kaplan-Meier Estimate , Liver/diagnostic imaging , Lymphoma, Non-Hodgkin/diagnostic imaging , Lymphoma, Non-Hodgkin/pathology , Male , Neoplasm Staging/methods , Neoplasm Staging/veterinary , Prognosis , Retrospective Studies , Spleen/diagnostic imaging , Survival , Ultrasonography/veterinary
3.
Vet Comp Oncol ; 14(1): 58-66, 2016 Mar.
Article in English | MEDLINE | ID: mdl-24102737

ABSTRACT

Ocular manifestations of lymphoma are described in humans and dogs but rarely in cats. In this prospective study, cats with newly diagnosed and treatment-naïve lymphoma were evaluated concerning clinical stage and ophthalmologic findings. Twenty-six cats were included. In 12 cats (48%), ocular changes were documented. Uveitis anterior and posterior were predominant findings, being present in 58% of affected individuals. Other findings included exophthalmos, corneal surface lesions and chemosis. Eight cats received chemotherapy, two of which had ocular involvement. In these two cats, a complete remission of an anterior and a partial remission of a posterior uveitis were documented. Due to the detection of ocular involvement, a stage migration from stage IV to V occurred in four patients. In the light of these findings, an opthalmological examination may be considered as an important part of staging in feline lymphoma as well as of follow-up examination in affected cats.


Subject(s)
Cat Diseases/pathology , Eye Diseases/veterinary , Lymphoma/veterinary , Animals , Cat Diseases/diagnosis , Cat Diseases/etiology , Cats , Eye Diseases/etiology , Lymphoma/complications , Lymphoma/pathology , Neoplasm Staging/veterinary , Prospective Studies
4.
Vet Comp Oncol ; 14 Suppl 1: 21-31, 2016 Aug.
Article in English | MEDLINE | ID: mdl-24548273

ABSTRACT

The aim of this prospective clinical trial was to investigate the efficacy and toxicity of a short-term, maintenance-free chemotherapy protocol in feline lymphoma. Twenty-six cats with confirmed diagnosis of high-/intermediate-grade lymphoma were treated with a 12-week protocol consisting of cyclic administration of l-asparaginase, vincristine, cyclophosphamide, doxorubicin and prednisolone. Complete (CR) and partial remission (PR) rates were 46 and 27%, respectively. Median duration of first CR was 394 days compared with a median PR duration of 41 days. No factor was identified to significantly influence the likelihood to reach CR. Overall survival amounted to 78 days (range: 9-2230 days). Median survival in CR cats was 454 days and in PR cats was 82 days. Toxicosis was mainly low grade with anorexia seen most frequently. In cats achieving CR, maintenance-free chemotherapy may be sufficient to attain long-term remission and survival. Factors aiding in prognosticating the likelihood for CR, strategies enhancing response and targeting chemotherapy-induced anorexia need to be identified in future.


Subject(s)
Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cat Diseases/drug therapy , Lymphoma, Non-Hodgkin/veterinary , Animals , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/adverse effects , Antineoplastic Agents/adverse effects , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/adverse effects , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Asparaginase/administration & dosage , Asparaginase/adverse effects , Cats , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Female , Lymphoma, Non-Hodgkin/drug therapy , Male , Neoplasm Staging , Prednisolone/administration & dosage , Prednisolone/adverse effects , Remission Induction , Survival Analysis , Vincristine/administration & dosage , Vincristine/adverse effects
5.
Article in English | MEDLINE | ID: mdl-22911255

ABSTRACT

OBJECTIVE: Aim of this study was to investigate epidemiologic and diagnostic characteristics of canine non-hematopoietic gastric neoplasia and to evaluate the surgical outcome of selected cases. MATERIAL AND METHODS: Patient data of dogs with histologically confirmed non-hematopoietic gastric tumors were reviewed and dogs with surgical intervention were followed up. RESULTS: 38 dogs were included into the evaluation. Histopathologic diagnoses comprised carcinoma/adenocarcinoma (n=33), gastrointestinal stromal tumor (GIST) (n=4), and leiomyoma (n=1). Patients' median age was 10 years, median weight was 20 kg and the male:female ratio was 1.4:1. The breeds represented by most individuals were Chow Chow, Collie, Hovawart and mixed-breed. Most frequent presenting complaint was vomiting. Only a low proportion of dogs were presented with anemia, thrombocytopenia or hypoproteinemia. In 58% of cases, ultrasonographic examination led to findings that were considered compatible with gastric neoplasia. Gastric wall thickening and loss of layering were the most common sonographic findings. Most frequent endoscopic findings were mucosal thickening and reddening; ulcerations were infrequent. Computed tomography findings were compatible with gastric neoplasia in two cases in which CT was performed. Intra-operative cytology results showed accordance with histologic diagnoses in 88% of cases. Five dogs with different underlying pathology and variable disease extension underwent surgical tumor resection. In one patient, recurrence was diagnosed after 104 days. Survival times of these dogs ranged between 7 and 2326 days. CONCLUSION AND CLINICAL RELEVANCE: Ultrasonography and, in selected cases, computed tomography aided in the diagnosis of gastric neoplasia. Intra-operative cytology possessed diagnostic value. In cases in which surgical resection was attempted, survival times varied markedly likely due to variable disease extension and underlying pathology (e.g. adenocarcinoma versus leiomyoma).


Subject(s)
Dog Diseases/diagnosis , Dog Diseases/epidemiology , Stomach Neoplasms/veterinary , Adenocarcinoma/diagnosis , Adenocarcinoma/epidemiology , Adenocarcinoma/surgery , Adenocarcinoma/veterinary , Age Distribution , Animals , Carcinoma/diagnosis , Carcinoma/epidemiology , Carcinoma/surgery , Carcinoma/veterinary , Dog Diseases/surgery , Dogs , Female , Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/epidemiology , Gastrointestinal Stromal Tumors/surgery , Gastrointestinal Stromal Tumors/veterinary , Leiomyoma/diagnosis , Leiomyoma/epidemiology , Leiomyoma/surgery , Leiomyoma/veterinary , Male , Retrospective Studies , Sex Distribution , Stomach Neoplasms/diagnosis , Stomach Neoplasms/epidemiology , Stomach Neoplasms/surgery , Treatment Outcome
6.
Article in German | MEDLINE | ID: mdl-22911259

ABSTRACT

The clinical case report describes diagnostics, therapy, response and outcome in a 7-year-old castrated male European Shorthair cat with renal lymphoma. By use of a combination chemotherapy, partial remission was achieved 8 days after induction, with a complete remission after 72 days. During chemotherapy the cat had a good quality of life. Adverse effects were limited to two episodes of vomiting and one short period of slight depression. At 629 days after the end of the chemotherapy, following 1449 days in remission, a relapse of the renal lymphoma was diagnosed. During the second chemotherapy, extension of the lymphoma to the CNS became apparent and the cat was euthanized after an overall survival time of 1509 days (4 years). The case shows that treating renal lymphoma in cats by adequate combination chemotherapy can achieve long survival times with a good quality of life.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cat Diseases/diagnosis , Cat Diseases/drug therapy , Kidney Neoplasms/veterinary , Lymphoma/veterinary , Animals , Cat Diseases/mortality , Cats , Central Nervous System Neoplasms/secondary , Central Nervous System Neoplasms/veterinary , Euthanasia, Animal , Fatal Outcome , Kidney Neoplasms/diagnosis , Kidney Neoplasms/drug therapy , Kidney Neoplasms/mortality , Lymphoma/diagnosis , Lymphoma/drug therapy , Lymphoma/mortality , Male , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/veterinary , Quality of Life , Remission Induction , Survival Rate
7.
Article in English, German | MEDLINE | ID: mdl-22911256

ABSTRACT

OBJECTIVE: Splenic masses have a high prevalence and are more common than diffuse splenic enlargement in dogs. It was the aim of the present study to retrospectively describe clinical aspects and histopathologic characteristics of dogs with splenic masses. MATERIAL AND METHODS: Records of patients with a histologically diagnosed splenic mass between January 2000 and March 2011 were reviewed. RESULTS: 249 dogs met the inclusion criteria and could be included in the study. Splenic masses were diagnosed histologically as non-malignant disease (n=117; 47%) and malignant splenic disease (n=132; 53%). Hemangiosarcoma was the most common histological diagnosis (n=97; 73.5%). Other malignant tumors included sarcoma (n=14), fibrohistiocytic nodules (n=9) as well as lymphoma, blastoma and adenocarcinoma. The non-malignant masses consisted of nodular hyperplasia (n=60), splenic hematoma (n=41), and splenitis (n=6). Dogs with hemoperitoneum had a higher frequency of splenic neoplasia. CONCLUSION: The results corroborate previous findings that hemangiosarcoma is the most frequent neoplasm of the canine spleen. However, in approximately half of the cases benign lesions were histologically diagnosed. CLINICAL RELEVANCE: It is essential that a frank discussion is held with owners regarding the prognosis associated with the treatment of dogs with a splenic mass associated with hemoperitoneum.


Subject(s)
Dog Diseases/epidemiology , Dog Diseases/pathology , Spleen/pathology , Splenic Neoplasms/veterinary , Abdomen/diagnostic imaging , Animals , Dog Diseases/surgery , Dogs , Female , Hemangiosarcoma/pathology , Hemangiosarcoma/surgery , Hemangiosarcoma/veterinary , Hematoma/pathology , Hematoma/veterinary , Hemoperitoneum/complications , Hemoperitoneum/epidemiology , Hemoperitoneum/veterinary , Immunohistochemistry/veterinary , Liver/diagnostic imaging , Male , Prognosis , Radiography, Abdominal/veterinary , Retrospective Studies , Sarcoma/pathology , Sarcoma/surgery , Sarcoma/veterinary , Spleen/diagnostic imaging , Splenectomy , Splenic Diseases/pathology , Splenic Diseases/veterinary , Splenic Neoplasms/epidemiology , Splenic Neoplasms/pathology , Splenic Neoplasms/surgery , Ultrasonography
8.
Article in English | MEDLINE | ID: mdl-22911257

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate whether changes in the left ventricular fractional shortening (LVFS) can be detected in dogs with malignant lymphoma undergoing a cyclic combination chemotherapy protocol including doxorubicin. HYPOTHESIS: Left ventricular fractional shortening as a stand-alone measurement will not show a significant change during the cyclic combination protocol. MATERIAL AND METHODS: In this retrospective study, the records of dogs with malignant lymphoma treated between April 2001 and October 2010 were reviewed. Inclusion criteria comprised: a diagnosis of malignant lymphoma, a cyclic combination chemotherapy (including L-asparaginase, vincristine, cyclophosphamide, doxorubicin and prednisolone), and an echocardiographic examination by an experienced examiner before treatment and after each doxorubicin administration. RESULTS: One hundred and eight dogs were included and a total of 446 LVFS measurements had been performed. Patients were divided into four groups according to the number of doxorubicin administrations. Median LVFS did not change significantly during the cyclic combination protocol in all groups. All median LVFS values remained above the lower reference value of 25%. CONCLUSION AND CLINICAL RELEVANCE: The measurement of LVFS did not show a significant change during the cyclic combination protocol treatment including doxorubicin in this population of dogs. Therefore either this cyclic combination protocol does not cause a systolic dysfunction or LVFS is not sensitive enough to detect early changes. Newer methods that are more sensitive then LVFS might be necessary to detect such changes.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Doxorubicin/administration & dosage , Lymphoma/veterinary , Ventricular Dysfunction, Left/veterinary , Animals , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Asparaginase/administration & dosage , Cyclophosphamide/administration & dosage , Dog Diseases/chemically induced , Dog Diseases/diagnostic imaging , Dogs , Doxorubicin/adverse effects , Female , Lymphoma/complications , Lymphoma/drug therapy , Male , Prednisolone/administration & dosage , Retrospective Studies , Ultrasonography , Ventricular Dysfunction, Left/chemically induced , Ventricular Dysfunction, Left/diagnostic imaging , Vincristine/administration & dosage
10.
Cytogenet Genome Res ; 135(1): 79-82, 2011.
Article in English | MEDLINE | ID: mdl-21811057

ABSTRACT

Human and canine lymphoid neoplasms are characterized by non-random cytogenetic abnormalities. However, due to the low mitotic activity of the B cells, cytogenetic analyses of B-cell lymphoid proliferations are difficult to perform. In the present study we stimulated canine B-cell lymphoma cells with the immunostimulatory CpG-oligonucleotide DSP30 in combination with interleukin-2 (IL-2) and obtained an adequate number of metaphases. Cytogenetic analyses revealed the loss of one X chromosome as the sole cytogenetic aberration. Chromosome analysis of the corresponding blood showed a normal female karyotype. Monosomy X as the sole clonal chromosomal abnormality is found in human hematopoietic malignancies as well, thus the dog may serve as a promising animal model.


Subject(s)
B-Lymphocytes/drug effects , Cell Culture Techniques/methods , Cytogenetics/methods , Dog Diseases , Lymph Nodes/pathology , Lymphoma, B-Cell , Monosomy , X Chromosome/chemistry , Animals , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Cells, Cultured , Dog Diseases/genetics , Dog Diseases/immunology , Dogs , Female , Humans , Interleukin-2/pharmacology , Karyotyping , Lymph Nodes/immunology , Lymphocyte Activation , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell/immunology , Metaphase , Oligonucleotides/pharmacology , X Chromosome/genetics
11.
Vet Comp Oncol ; 9(2): 131-40, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21569198

ABSTRACT

Appendicular osteosarcoma (OSA) is a highly metastatic tumour in dogs. The aim of the study was to compare thoracic radiographs with thoracic computed tomography (CT) in the staging of canine appendicular OSA. In all, 39 canine patients histologically diagnosed with OSA were reviewed in the retrospective study. All dogs underwent radiographic examination as well as CT examination of the thoracic cavity. Pulmonary nodules were detected radiographically in two cases (5%), whereas the CT imaging showed that pulmonary nodules were evident in 11 cases (28%, P = 0.024). There was an improved detection of small pulmonary nodules in the lung parenchyma with CT (P = 0.021). The number of nodules in CT examination had a significant negative influence on survival time (P = 0.005). However, whether nodules were present in CT or not did not influence overall survival (P = 0.368). CT examination was superior to thoracic radiography in the screening and detection of pulmonary nodules in dogs with OSA.


Subject(s)
Bone Neoplasms/veterinary , Dog Diseases/diagnostic imaging , Lung Neoplasms/veterinary , Multiple Pulmonary Nodules/veterinary , Osteosarcoma/veterinary , Tomography, X-Ray Computed/veterinary , Animals , Bone Neoplasms/pathology , Dog Diseases/mortality , Dogs , Female , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/mortality , Lung Neoplasms/secondary , Male , Multiple Pulmonary Nodules/diagnostic imaging , Multiple Pulmonary Nodules/mortality , Multiple Pulmonary Nodules/secondary , Osteosarcoma/diagnostic imaging , Osteosarcoma/mortality , Osteosarcoma/secondary , Proportional Hazards Models , Retrospective Studies
12.
Cytogenet Genome Res ; 132(1-2): 16-21, 2011.
Article in English | MEDLINE | ID: mdl-20668368

ABSTRACT

Besides man, the dog is the only known mammalian species that spontaneously develops carcinomas of the prostate with considerable frequency. For this reason, the dog is considered to be the only useful animal model for spontaneously occurring prostate malignancies in man. Cytogenetic investigations of human prostate cancers have revealed the frequent occurrence of trisomies 7, 8, and 17. Chromosome analyses of canine prostate carcinomas are rare. In this report we present 2 cases of canine prostate cancer showing a clonal polysomy 13 along with complex karyotype changes. Along with a previous report demonstrating polysomy 13 as the only karyotype deviation in a canine prostate cancer the present report supports the hypothesis that in canine prostate cancer, polysomy 13 is a recurrent cytogenetic aberration linked to the development of the disease. As human chromosomes (HSA) 8q and 4q and the canine chromosome (CFA) 13 share high homology, these results suggest that a conserved area on these chromosomes is involved in tumorigenesis in both species.


Subject(s)
Chromosome Mapping/veterinary , Prostatic Neoplasms/genetics , Animals , Dogs , Karyotyping , Male , Prostatic Neoplasms/pathology
13.
Vet Comp Oncol ; 8(2): 87-95, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20579321

ABSTRACT

Overexpression of high mobility group A (HMGA) genes was described as a prognostic marker in different human malignancies, but its role in canine haematopoietic malignancies was unknown so far. The objective of this study was to analyse HMGA1 and HMGA2 gene expression in lymph nodes of canine lymphoma patients. The expression of HMGA1 and HMGA2 was analysed in lymph node samples of 23 dogs with lymphoma and three control dogs using relative quantitative real-time RT-PCR. Relative quantity of HMGA1 was significantly higher in dogs with lymphoma compared with reference samples. HMGA2 expression did not differ between lymphoma and control dogs. With the exception of immunophenotype, comparison of disease parameters did not display any differences in HMGA1 and HMGA2 expression. The present findings indicate a role of HMGA genes in canine lymphoma. This study represents the basis for future veterinary and comparative studies dealing with their diagnostic, prognostic and therapeutic values.


Subject(s)
Dog Diseases/genetics , HMGA Proteins/biosynthesis , Lymphoma/veterinary , Animals , Case-Control Studies , Dogs , Female , Gene Expression Regulation, Neoplastic/genetics , Genes/genetics , HMGA Proteins/analysis , Lymph Nodes/chemistry , Lymphoma/genetics , Male , Reverse Transcriptase Polymerase Chain Reaction/veterinary
14.
Vet Comp Oncol ; 8(2): 127-37, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20579326

ABSTRACT

Elevated high-mobility group box 1 (HMGB1) levels have been demonstrated in different human neoplasias. Information on serum HMGB1 before and during chemotherapy is lacking, as is data pertaining to its prognostic significance. The aim of this study was to characterize serum HMGB1 level in dogs with lymphoma and to assess its influence on the outcome following chemotherapy. Serum HMGB1 concentrations were measured in 16 dogs with lymphoma before treatment (W1) and on weeks 2 (W2), 6 (W6) and 12 (W12) of treatment with chemotherapy. Initial serum HMGB1 levels were significantly higher than HMGB1concentrations in control dogs and the levels in W2, W6 and W12. HMGB1-W1 concentrations were lower in dogs achieving complete remission than that in the single dog with partial remission. The ratio W12/W6 exhibited significant influence on remission duration. In these dogs with lymphoma, serum HMGB1 was elevated in comparison with that in controls. Initial serum HMGB1 level and its modulation during treatment may possess prognostic value.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/blood , Dog Diseases/blood , HMGB1 Protein/blood , Lymphoma/veterinary , Animals , Case-Control Studies , Cyclophosphamide/administration & dosage , Dog Diseases/diagnosis , Dog Diseases/drug therapy , Dogs , Doxorubicin/administration & dosage , Enzyme-Linked Immunosorbent Assay/veterinary , Female , Lymphoma/blood , Lymphoma/diagnosis , Lymphoma/drug therapy , Male , Prognosis , Treatment Outcome , Vincristine/administration & dosage
15.
J Vet Intern Med ; 24(2): 384-90, 2010.
Article in English | MEDLINE | ID: mdl-20102496

ABSTRACT

BACKGROUND: The presence of cytotoxic drug residues in urine of dogs may represent an exposure risk for pet owners and other people as well as a potential environmental contaminant. However, studies on cytotoxic drug residues in excretions of clinical patients are lacking in veterinary oncology. HYPOTHESIS: Variable concentrations of cytotoxic residues are present in urine samples, depending on sampling time and substance. ANIMALS: Client-owned dogs with lymphoma or mast cell tumors treated with standard chemotherapy protocols. METHODS: Urine samples were collected before, directly after, and on days after administration of chemotherapy. Measurement of vincristine, vinblastine, cyclophosphamide, and doxorubicin residues in canine urine was performed by a quantitative liquid chromatography tandem mass spectrometry (LC/MS/MS) method. RESULTS: Median cyclophosphamide residue concentration was 398.2 microg/L directly after treatment (d0) and was below the level of detection on days 1-3 (d1, d2, d3). Median vincristine residue concentration was 53.8 microg/L directly after treatment and was 20.2, 11.4, and 6.6 microg/L on days 1, 2, and 3. Median vinblastine residues were 144.9 (d0), 70.8 (d1), 35.6 (d2), and 18.7 microg/L (d3) with low concentrations detectable for 7 days after treatment. Median urine doxorubicin concentrations were 354.0 (d0), 165.6 (d1), 156.9 (d2), and 158.2 microg/L (d3). Low concentrations of doxorubicin were measurable up to 21 days after administration. CONCLUSIONS AND CLINICAL IMPORTANCE: Variable concentrations of chemotherapeutics were measured in urine samples, depending on sampling time point and drug. Findings may inform current chemoprotection guidelines and help minimize exposure risks.


Subject(s)
Antineoplastic Agents/urine , Dog Diseases/urine , Drug Residues/analysis , Lymphoma/veterinary , Mast-Cell Sarcoma/veterinary , Animals , Antineoplastic Agents/chemistry , Cyclophosphamide/urine , Dogs , Doxorubicin/urine , Environmental Exposure , Lymphoma/drug therapy , Mast-Cell Sarcoma/drug therapy , Vinblastine/urine , Vincristine/urine
16.
J Vet Intern Med ; 24(2): 379-83, 2010.
Article in English | MEDLINE | ID: mdl-20102504

ABSTRACT

BACKGROUND: The presence of drug residues in blood samples can represent an occupational hazard. However, studies on cytotoxic drug residues in serum of dogs are lacking in veterinary oncology. OBJECTIVE: To evaluate possible occupational hazards associated with handling of blood samples from dogs receiving oncolytic drugs 7 days after treatment. ANIMALS: Twenty-seven client-owned dogs treated for lymphoma or mast cell tumors with vincristine, vinblastine, cyclophosphamide, or doxorubicin. METHODS: Prospective, observational study. Serum samples were either taken 7 days after administration of vincristine, cyclophosphamide, doxorubicin (lymphoma), and vinblastine (mast cell tumor), or 1-2 days after the last concurrent oral administration of cyclophosphamide (mast cell tumor). Additionally, serum was collected within 5 minutes of treatment. Measurement of drug residues in serum was performed by liquid chromatography tandem mass spectrometry (LC/MS/MS). RESULTS: In 33 samples collected within 5 minute of treatment, the median serum concentrations were vincristine: 37 microg/L (range: 11-87 microg/L), vinblastine: 13 microg/L (range: 13-35 microg/L), cyclophosphamide: 2,484 microg/L (range: 1,209-2,778 microg/L), doxorubicin: 404 microg/L (range: 234-528 microg/L). In 81 serum samples collected 7 days after treatment vinblastine (7 microg/L) was detected in 1 sample, and cyclophosphamide (7 and 9 microg/L) in 2 samples collected 1-2 days after oral administration of cyclophosphamide. Medications were not detected in any of the other samples. CONCLUSIONS AND CLINICAL IMPORTANCE: Handling of blood samples from dogs receiving oncolytic chemotherapy 7 days after treatment with vincristine, vinblastine, cyclophosphamide, and doxorubicin should not present a health hazard.


Subject(s)
Antineoplastic Agents/blood , Dog Diseases/drug therapy , Drug Residues/analysis , Medical Laboratory Personnel , Occupational Exposure , Veterinarians , Animals , Antineoplastic Agents/chemistry , Dog Diseases/blood , Dogs , Drug Residues/adverse effects , Lymphoma/drug therapy , Lymphoma/veterinary , Mast-Cell Sarcoma/drug therapy , Mast-Cell Sarcoma/veterinary , Occupational Exposure/adverse effects , Occupational Exposure/analysis , Prospective Studies , Risk Factors
17.
Vet J ; 183(3): 298-304, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19185520

ABSTRACT

The purpose of this study was to examine the influence of cyclic combination chemotherapy on primary haemostasis in dogs with malignant lymphoma. Seventeen dogs receiving cytostatic treatment for high-grade lymphoma were included in the study. The dogs were treated with a Madison-Wisconsin derived protocol, which included asparaginase, vincristine, doxorubicin and prednisolone. At different time points during the first 4 weeks of induction, platelet count, capillary bleeding time, analysis of the platelet function using the platelet function analyser PFA-100, and platelet aggregation by the Born-method were measured. The most obvious changes were found for median values of the platelet count, which increased significantly from 210,000/microL before induction to 349,000/microL during the second week of induction (P=0.0010). Median platelet count subsequently decreased by the fourth week of treatment (Friedman-test: P<0.0001). None of the parameters of platelet function (capillary bleeding time, automatic platelet function analysis, aggregation maximum) showed significant changes with time (P>0.05, Friedman-test). The results did not suggest that significant platelet dysfunction was induced by the chemotherapeutic protocol used in the study.


Subject(s)
Antineoplastic Agents/therapeutic use , Dog Diseases/drug therapy , Lymphoma/veterinary , Animals , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Asparaginase/therapeutic use , Bleeding Time , Dogs , Doxorubicin/therapeutic use , Female , Lymphoma/drug therapy , Male , Platelet Aggregation/drug effects , Platelet Count/veterinary , Platelet Function Tests/veterinary , Prednisolone/therapeutic use , Vincristine/therapeutic use
18.
J Vet Intern Med ; 22(2): 394-400, 2008.
Article in English | MEDLINE | ID: mdl-18312554

ABSTRACT

BACKGROUND: Different chemotherapy regimes have been described for feline lymphoma with varying outcomes. HYPOTHESIS: In cats with lymphoma, a long-term, multiagent chemotherapy protocol will be effective and carry acceptable toxicity. ANIMALS: Twenty-three cats with histologically or cytologically confirmed diagnosis of lymphoma. METHODS: Prospective, single-arm clinical trial in which cats were treated with a chemotherapy protocol consisting of a cyclic combination of l-asparaginase, vincristine, cyclophosphamide, doxorubicin, methotrexate, and prednisolone with a planned total treatment time of 122 weeks. RESULTS: Complete remission (CR) rate was 74% (n = 17). Fourteen percent of cats attained partial remission (PR). Median duration of first CR was 264 days (range, 45-2,485 days). Six-month, 1-, and 2-5-year remission rates were 75, 50, and 34%, respectively. Duration of PR ranged between 23 and 63 days. Median survival in cats with CR was 296 days (range, 50-2,520 days). Six-month, 1-, 2-, and 3-5-year survival rates in cats with CR were 82, 47, 34, and 27%, respectively. Survival of cats achieving PR ranged between 38 and 120 days. Of the analyzed variables, only anatomical location had a significant influence on remission duration (P=.022). Actual median treatment time in cats with CR was 128 days (18 weeks). Hematologic and gastrointestinal toxicosis was infrequent and mostly low grade. CONCLUSIONS AND CLINICAL IMPORTANCE: In this population of cats with lymphoma, chemotherapy was effective. With infrequent and mostly low-grade toxicosis, tolerability of the protocol may be considered good.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cat Diseases/drug therapy , Lymphoma/veterinary , Animals , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Asparaginase/administration & dosage , Cats , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Drug Administration Schedule/veterinary , Female , Lymphoma/drug therapy , Male , Methotrexate/administration & dosage , Prednisolone/administration & dosage , Treatment Outcome , Vincristine/administration & dosage
19.
J Vet Intern Med ; 20(4): 948-54, 2006.
Article in English | MEDLINE | ID: mdl-16955821

ABSTRACT

BACKGROUND: Treatment of lymphoma in dogs by long-term chemotherapy has favorable results. However, the efficacy of short-term, maintenance-free treatment protocols on remission and survival times in dogs has not been determined. HYPOTHESIS: That treatment using a 12-week chemotherapy protocol would be associated with satisfactory treatment outcome in dogs with lymphoma. ANIMALS: 77 dogs with histologically or cytologically confirmed diagnosis of lymphoma. METHODS: Prospective clinical trial in which dogs were treated with a 12-week chemotherapy protocol consisting of L-asparaginase, vincristine, cyclophosphamide, doxorubicin, and prednisolone. RESULTS: Complete remission rate was 76.3%. Multivariate logistic regression analysis revealed that clinical substage (P = .006) and immunophenotype (P = .003) had a significant influence on the likelihood of a dog achieving complete remission. Median duration of first complete remission was 243 days (range 19-1,191 days). The 6-month, 1-year, and 2-year remission rates were 68%, 28%, and 16%, respectively. In the multivariate analysis of patient variables, immunophenotype (P = .022) revealed a significant influence on first remission duration. Toxicosis was mild with the exception of 1 treatment-associated death. CONCLUSIONS AND CLINICAL IMPORTANCE: In this group of dogs the 12-week maintenance-free chemotherapy protocol was well tolerated and had satisfactory results.


Subject(s)
Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Lymphoma/veterinary , Animals , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Asparaginase/administration & dosage , Asparaginase/adverse effects , Asparaginase/therapeutic use , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Cyclophosphamide/therapeutic use , Dogs , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Lymphoma/drug therapy , Prednisolone/administration & dosage , Prednisolone/adverse effects , Prednisolone/therapeutic use , Vincristine/administration & dosage , Vincristine/adverse effects , Vincristine/therapeutic use
20.
J Hered ; 96(7): 782-5, 2005.
Article in English | MEDLINE | ID: mdl-15994418

ABSTRACT

Akin to the situation in humans, dogs are frequently affected by tumors of the prostate. The malignancies share many similarities between both species, for example, median age at the onset of the disease and metastatic behavior. In human prostatic tumor samples, investigations of prepared metaphase spreads showed a variety of chromosomal aberrations, with trisomies of chromosomes 7, 8, and 17 as the leading cytogenetic abnormalities. In this article we present one case of a canine adenocarcinoma of the prostate, including clinical examination and establishment of a cell line from a tumor sample obtained from the affected 10-year-old male Briard. Searching for similarities between both species in respect to chromosomal changes within the tumor samples, we investigated prepared metaphases of the canine cell line cytogenetically. These investigations presented a highly rearranged karyotype showing a large biarmed marker consisting of material from chromosomes 1 and 2 in addition to centromeric fusions between dog chromosomes 1 and 5 that both could be identified in every metaphase investigated, while centric fusions of chromosomes 4 and 5 occurred in up to 50% of the metaphases. The cell line grew very well and showed evidence of being spontaneously immortalized when it crossed the 20th passage.


Subject(s)
Adenocarcinoma/veterinary , Chromosome Aberrations/veterinary , Dog Diseases/genetics , Dog Diseases/pathology , Prostatic Neoplasms/veterinary , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Animals , Cell Line, Tumor , Dogs , Male , Metaphase/genetics , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Translocation, Genetic/genetics , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...